Slide 1: Conference on FY2024.12 Financial Results
Conference on FY2024.12 Financial Results 30 January 2025 CHUGAI PHARMACEUTICAL CO., LTD.
Slide 2: Important Reminder
Important Reminder Forward-Looking Statements This presentation may include forward-looking statements pertaining to the business and prospects of Chugai Pharmaceutical Co., Ltd. (the “Company”). These statements reflect the Company’s current analysis of existing information and trends. Actual resul
Slide 3: Agenda
Agenda 01 FY2024 Overview and FY2025 Forecast President & CEO Dr. Osamu Okuda Head of R&D Portfolio Management Dept., 02 Overview of Development Pipeline Project & Lifecycle Management Unit Dr. Michiaki Tanaka 03 FY2024 Consolidated Financial Overview (Core) Director, Executive Vice President & CFO
Slide 4: Overview and FY2025 Forecast
FY2024 Overview and FY2025 Forecast President & CEO Dr. Osamu Okuda
Slide 5: 2024 Financial Performance
FY2024 Overview and FY2025 Forecast 2024 Financial Performance Achieved record-high revenue, operating profit and net income, exceeding the revised forecast Revenue exceeded 1 trillion JPY for the third consecutive fiscal year, and operating profit surpassed 500 billion JPY for the first time. O
Slide 6: 2025 Forecast
FY2024 Overview and FY2025 Forecast 2025 Forecast Revenue and operating profit are expected to increase to 1,190.0 billion JPY (+1.7%, YoY) and 570.0 billion JPY (+2.5%, YoY), respectively Revenue and profits are expected to reach a record high mainly due to growth in overseas sales. Operating m
Slide 7: Topline Analysis of 2025 Forecast
FY2024 Overview and FY2025 Forecast Topline Analysis of 2025 Forecast Overseas sales 【Billions of JPY】 +18.7 -19.0 Domestic sales Domestic sales Sales ＋18.3 volume etc. Slight increase due to growth in +1.4 Other new products Phesgo and PiaSky, ROY/PS Export unit income operating as well as main p
Slide 8: Review of Strategic Policies for 2024 (1/2)
FY2024 Overview and FY2025 Forecast Review of Strategic Policies for 2024 (1/2) Steady progress in drug discovery and open innovation Discontinuation or plan change in some In-house early development ●Progress development of mid-size molecule projects The number of projects transferring to PC ac
Slide 9: Review of Strategic Policies for 2024 (2/2)
FY2024 Overview and FY2025 Forecast Review of Strategic Policies for 2024 (2/2) Progressing smoothly including global approvals for in-house products and growth of key drivers Strengthen business foundation progressing well, despite challenges in talent acquisition ●Progress as planned ●Issues i
Slide 10: Management Policies for 2025
FY2024 Overview and FY2025 Forecast Management Policies for 2025 Addressing ‘Enhance RED functions and creation of value’, ‘Maximize value of LCM projects’, and ‘Strengthen business foundation’ 1. Enhance RED functions and 2. Maximize value of 3. Strengthen business foundation creation of value LC
Slide 11: New Value Creation Model
FY2024 Overview and FY2025 Forecast New Value Creation Model A process for creating shared value using materiality as an axes Our growth and Creation of shared value Social growth and development through increase in corporate Realization of advanced and sustainable development by value patient-cen
Slide 12: For the Sake of Patients - Innovations for the Next 100 Years
FY2024 Overview and FY2025 Forecast For the Sake of Patients - Innovations for the Next 100 Years - Since our founding, we have consistently carried on the spirit of "Creating drugs that benefit the world" Through bold challenges, we have relentlessly pursued drug discovery unique to us, for the
Slide 13: Outlook of Mid- to Long-term Growth
FY2024 Overview and FY2025 Forecast Outlook of Mid- to Long-term Growth Roche products will continue to be a stable revenue base. Aim for growth through contribution to people worldwide with in-house products. NEMLUVIO US approval in 2024 (AD, PN), filing in EU and several countries 2bn+ USD Alece
Slide 14: Capital Allocation Policy
FY2024 Overview and FY2025 Forecast Capital Allocation Policy Chugai is committed to appropriately allocating capital to provide solutions that create value for patients and deliver stable returns to shareholders. This commitment aligns with its mission: “Dedicate ourselves to adding value by creati
Slide 15: Contribution to Shareholders
FY2024 Overview and FY2025 Forecast Contribution to Shareholders An annual dividends of 98 yen per share (57 yen at year-end) is planned for 2024 In 2025, an annual dividends of 250 yen per share is expected, which includes a regular dividends of 100 yen per share and 100th anniversary dividends
Slide 16: Summary
FY2024 Overview and FY2025 Forecast Summary In 2024, revenue, operating profit, and net income exceeded revised forecasts, all reaching record highs. Revenue surpassed 1 trillion yen for the third consecutive year, and operating profit exceeded 500 billion yen for the first time. In 2025, we exp
Slide 17: Overview of Development Pipeline
Overview of Development Pipeline Head of R&D Portfolio Management Dept., Project & Lifecycle Management Unit Dr. Michiaki Tanaka
Slide 18: Q4 Topics (1/2)
Overview of Development Pipeline Q4 Topics (1/2) As of January 30, 2025 Moderate-to-severe atopic dermatitis (additional indication) December 2024 (U.S.) NEMLUVIO® (nemolizumab)* Moderate-to-severe atopic dermatitis and prurigo nodularis (CHMP positive December 2024 (EU) opinion) Approved Rituxan Ch
Slide 19: Q4 Topics (2/2)
Overview of Development Pipeline Q4 Topics (2/2) As of January 30, 2025 Lunsumio Four-year data from P2 (GO29781) study in r/r follicular lymphoma December 2024 Medical Conference Five- year data from POLARIX study (P3) in previously untreated Polivy diffuse large B-cell lymphoma (DLBCL) December 20
Slide 20: 2024: Key R&D Milestones
Overview of Development Pipeline 2024: Key R&D Milestones Underlined and bolded are new progress since October 25, 2024 Product Indication / Study name Progress Approved PiaSky Paroxysmal nocturnal hemoglobinuria (PNH) (Japan/EU/U.S.） (Japan/U.S./EU) Projects to be Approved Approved Alecensa Non-sma
Slide 21: 2025: Key R&D Milestones
Overview of Development Pipeline 2025: Key R&D Milestones As of January 30, 2025 Product Indication / Study name Progress delandistrogene Projects to be Duchenne muscular dystrophy moxeparvovec Approved Vabysmo Angioid streaks COMMUTE-a study*: PiaSky atypical hemolytic uremic syndrome（aHUS） SUNMO s
Slide 22: AID351: Dengue fever
Overview of Development Pipeline AID351: Dengue fever In January 2025, Chugai and GSK entered into a collaboration agreement to develop AID351 for the treatment of dengue fever, a neglected tropical disease†. Both companies will work together to explore opportunities in global health R&D. Antibo
Slide 23: Early Development Strategy to Evaluate Drug Potential in the Shortest Time (1/2)
Overview of Development Pipeline Early Development Strategy to Evaluate Drug Potential in the Shortest Time (1/2) From preclinical stage, determine optimal development route, precise Go/No-Go criteria, and effective development plans Steadily progress towards the realization of TOP I 2030 by mak
Slide 24: Early Development Strategy to Evaluate Drug Potential in the Shortest Time (2/2)
Overview of Development Pipeline Early Development Strategy to Evaluate Drug Potential in the Shortest Time (2/2) Orange: Newly added or modified Acceleration strategy for high-potential projects Up to now • Projects with high-potential expected from the preclinical stage D.E. part C.E. part ePoC •
Slide 25: Potential Market Sales of Main Projects
Overview of Development Pipeline Potential Market Sales of Main Projects As of January 30, 2025 Domestic Sales In-house products Indications Domestic Sales*1 Peak Sales Year Changes from Previous Disclosure Overseas Sales Hemlibra Hemophilia A, Acquired Hemophilia A 50 bn+ JPY -2030 ー <Projects lice
Slide 26: Portfolio of Each Modality
Overview of Development Pipeline Portfolio of Each Modality As of January 30, 2025 Drug Discovery Pre-clinical development Clinical Launched AMY109 Enspryng Antibody drugs, cellular and gene therapy products NXT007 (MOGAD, AIE, TED/P3) Actemra DONQ52 PiaSky Hemlibra RAY121 (aHUS/P3, SCD/P2) Enspryng
Slide 27: Projected Submissions (Post PoC NMEs and Products)
Overview of Development Pipeline Projected Submissions (Post PoC NMEs and Products) Filed As of January 30, 2025 NME Line extension VABYSMO TECENTRIQ In-house (RG7716) (RG7446) Angioid streaks Alveolar soft part sarcoma In-licensed (Roche) new entry delandistrogene TECENTRIQ moxeparvovec *Before obt
Slide 28: Projects under Development (1/2)
Overview of Development Pipeline Projects under Development （1/2） As of January 30, 2025 Phase I Phase II Phase III Filed LUNA18 RG7421 / AF802 (RG7853) / Alecensa RG6171 /giredestrant RG7446 / Tecentriq - Solid tumors cobimetinib - NSCLC(stage Ⅲ)* - BC (adjuvant) - Alveolar soft part - Solid tumors
Slide 29: Projects under Development (2/2)
Overview of Development Pipeline Projects under Development（2/2） As of January 30, 2025 Phase I Phase II Phase III Filed RG7935 / prasinezumab GYM329 (RG6237) SA237 (RG6168) / Enspryng RG6356 / - Parkinson's disease - SMA - MOGAD delandistrogene RG6102/trontinemab (combination with - AIE moxeparvove
Slide 30: In-house Products GYM329 / NXT007: Current Status
Overview of Development Pipeline In-house Products GYM329 / NXT007: Current Status Both will achieve major milestones in 2025 Product Indication P1 P2 P3 Features of GYM329 GYM329 SMA P2/3 Readout in 2025 Anti-latent myostatin antibody applying Sweeping Antibody® FSHD P2 Readout in 2025 Inhi
Slide 31: Small Molecule Drug Discovery: Portfolio
Overview of Development Pipeline Small Molecule Drug Discovery: Portfolio As of January 30, 2025 In-house molecule REVN24 Alecensa Alecensa (Acute (Maintenance (NSCLC, NSCLC disease/P1) treatment of adjuvant) Cancer NSCLC(stage Ⅲ) after Edirol chemoradiotherapy (Osteoporosis) /P3) Oxarol (Psoriasis)
Slide 32: Mid-Size Molecule Drug Discovery: Portfolio
Overview of Development Pipeline Mid-Size Molecule Drug Discovery: Portfolio As of January 30, 2025 Chronic Cancer Acute Cancer Cancer disease disease LUNA18 (Pan-RAS) Chronic Cancer disease Cancer Chronic Cancer disease Chronic Cancer disease Drug Discovery Pre-clinical 前臨床開発 臨床試験 Clinical developm
Slide 33: Antibody Drug, Cellular and Gene Therapy: Portfolio
Overview of Development Pipeline Antibody Drug, Cellular and Gene Therapy: Portfolio As of January 30, 2025 AMY109 Enspryng Actemra Established technologies (Endometriosis/P2) (MOGAD, AIE, (Rheumatoid arthritis etc.) NXT007 TED/P3) (Hemophilia A/P1/2) Hemlibra DONQ52 PiaSky (Hemophilia A etc.) (Celi
Slide 34: Advances in Major Chugai Originated Projects Out-Licensed to 3rd Parties (1/2)
Overview of Development Pipeline Advances in Major Chugai Originated Projects Out-Licensed to 3rd Parties (1/2) As of January 30, 2025 Generic name/ Mode of Granted rights to Development Licensee Indication Stage Progress Action licensee code U.S. FDA BTD（recurrent LGSOC in combination with defact
Slide 35: Advances in Major Chugai Originated Projects Out-Licensed to 3rd Parties (2/2)
Overview of Development Pipeline Advances in Major Chugai Originated Projects Out-Licensed to 3rd Parties (2/2) As of January 30, 2025 Generic name/ Granted rights to Development Mode of Action Licensee Indication Stage Progress licensee code FDA BLA / EMA MAA accepted in Feb 2024 + consortium Ato
Slide 36: FoundationOne CDx Cancer Genomic Profile - Companion diagnostic indications
Overview of Development Pipeline FoundationOne CDx Cancer Genomic Profile -Companion diagnostic indications- As of January 30, 2025 Alterations Cancer type Relevant drugs Activating EGFR alterations afatinib maleate, erlotinib hydrochloride, gefitinib, osimertinib mesilate, dacomitinib hydrate EGFR
Slide 37: FoundationOne Liquid CDx Cancer Genomic Profile
Overview of Development Pipeline FoundationOne Liquid CDx Cancer Genomic Profile -Companion diagnostic indications- As of January 30, 2025 Alterations Cancer type Relevant drugs Activating EGFR alterations afatinib maleate, erlotinib hydrochloride, gefitinib, osimertinib mesilate EGFR exon 20 T790M
Slide 38: FY2024 Q4 Consolidated Financial Overview (Core)
FY2024 Q4 Consolidated Financial Overview(Core) Director, Executive Vice President & CFO Iwaaki Taniguchi
Slide 39: P/L Jan – Dec (Year on Year)
FY2024 Consolidated Financial Overview (Core) P/L Jan – Dec (Year on Year) STRICTLY CONFIDENTIAL Domestic sales (Billions of JPY) 2023 2024 Growth Decrease due to the absence of supply of Ronapreve (81.2 billion Revenue 1,111.4 1,170.6 + 59.2 + 5.3% JPY) to the government recorded in the same period
Slide 40: Sales Jan – Dec (Year on Year)
FY2024 Consolidated Financial Overview (Core) Sales Jan – Dec (Year on Year) STRICTLY CONFIDENTIAL (Billions of JPY) Sales by Disease Area, Sales by Product, Year on Year Year on Year ( ): Actual sales in FY2024 %: Year-on-year percentage change *included in Other products of Specialty +23.4, +2.4%
Slide 41: Operating Profit Jan – Dec (Year on Year)
FY2024 Consolidated Financial Overview (Core) Operating Profit Jan – Dec (Year on Year) STRICTLY CONFIDENTIAL (Billions of JPY) -27.7 Overseas sales +120.3 +73.9 Increase in Domestic sales various costs -96.9 and decrease in Decrease in other +35.8 cost of sales operating NHI drug price income revis
Slide 42: Structure of Costs and Profit by Quarter
FY2024 Consolidated Financial Overview (Core) Structure of Costs and Profit by Quarter STRICTLY CONFIDENTIAL (Billions of JPY) Year on Year (vs. 2023 Q4) % of Revenue (% of sales for Cost of sales ratio: cost to sales ratio improved due to a cost of sales) change in product mix, etc. R&D: increase d
Slide 43: Structure of Revenue by Quarter
FY2024 Consolidated Financial Overview (Core) Structure of Revenue by Quarter STRICTLY CONFIDENTIAL (Billions of JPY) Year on Year (vs. 2023 Q4) % of Revenue Domestic sales: same level as the previous year due to growth of mainstay products, despite the NHI drug price revisions and market penetratio
Slide 44: P/L Jan – Dec (vs. Revised Forecast)
FY2024 Consolidated Financial Overview (Core) P/L Jan – Dec (vs. Revised Forecast) STRICTLY CONFIDENTIAL 2024 Domestic sales Outperformed the forecast due to favorable progress (Billions of JPY) Reivised Achiev. Actual +/- of mainstay products Forecast Revenue 1,150.0 1,170.6 + 20.6 101.8% Overseas
Slide 45: Sales Jan – Dec (vs. Revised Forecast)
FY2024 Consolidated Financial Overview (Core) Sales Jan – Dec (vs. Revised Forecast) STRICTLY CONFIDENTIAL (Billions of JPY) Sales by Disease Area, Sales by Product, Year on Year Year on Year ( ): Actual sales in FY2024 %: Achievement *included in Other products of Specialty +11.9, 101.2% (307.7） Ov
Slide 46: Impact from Foreign Exchange Jan – Dec
FY2024 Consolidated Financial Overview (Core) Impact from Foreign Exchange Jan – Dec STRICTLY CONFIDENTIAL vs.2023 vs.2024 2023 2024 2024 Actual rate Revised Exchange Actual rate*2 Revised Actual rate*2 (Billions of JPY) Forecast rate Rate Forecast rate (JPY) Jan - Dec Jan - Dec Jan -Dec 【C】vs.【A】 【
Slide 47: Financial Position (vs. 2023 Year End)
FY2024 Consolidated Financial Overview (Core) Financial Position (vs. 2023 Year End) STRICTLY (Billions of JPY) CONFIDENTIAL Total assets 1,932.5 + 275.9 2,208.4 Total liabilities -307.0 ＋0.1 -306.9 Increase in net working capital 1,625.6 Total net assets 1,901.5 Increase mainly due to a decrease in
Slide 48: Net Cash (vs. 2023 Year End)
FY2024 Consolidated Financial Overview (Core) Net Cash (vs. 2023 Year End) STRICTLY CONFIDENTIAL (Billions of JPY) Total investment -28.8 Income tax Operating profit after adjustment *1 +584.8 Increase -62.5 payable, etc. in net Operating profit *1 +542.0 working -106.6 Dividends paid Depreciation,
Slide 49: ROIC
FY2024 Consolidated Financial Overview (Core) ROIC 44.3% Core operating profit after tax【A】 STRICTLY 42.9% CONFIDENTIAL 37.3% Steady increase due to export and royalty income for 36.1% 34.6% Hemlibra ROIC* NOA【B】 999.3 947.6 Increase mainly in long-term net operating assets due to 900.9 aggressi
Slide 50: P/L 2025 Forecast
FY2024 Consolidated Financial Overview (Core) P/L 2025 Forecast STRICTLY CONFIDENTIAL 2024 2025 Growth Domestic sales (Billions of JPY) Increase due to sales growth of new products and mainstay Actual Forecast products, despite decrease due to the NHI price revisions Revenues 1,170.6 1,190.0 + 19.4
Slide 51: Sales 2025 Forecast
FY2024 Consolidated Financial Overview (Core) Sales 2025 Forecast STRICTLY CONFIDENTIAL (Billions of JPY) Sales by Disease Area Sales by Product ( ): Forecast sales in FY2025 %: Year-on-year percentage change Excluding products out-licensed 3rd parties +20.1, +2.0 % (25.5） (324.2） (11.9） (31.6） Over
Slide 52: P/L Jan – Dec (Non-core adjustment)
FY2024 Consolidated Financial Overview (Core) P/L Jan – Dec (Non-core adjustment) STRICTLY CONFIDENTIAL Non-core items Non-core items IFRS Core (Billions of JPY) Intangible Factors affected operating profit results Others results assets Intangible assets Revenue 1,170.6 1,170.6 Sales 997.9 997.9 Amo
Slide 53: Current Status / Plan for Major Investments
FY2024 Consolidated Financial Overview (Core) Current Status / Plan for Major Investments STRICTLY CONFIDENTIAL Planned investment Start of Planned ~2023 2024 2025 2026 2027 2028 2029~ Investment investment completion Total amount Unit to-date Fujieda plant FJ3: Manufacture APIs of small and mid-siz
Slide 54: Summary of Chugai Originated Global Products
FY2024 Consolidated Financial Overview (Core) Summary of Chugai Originated Global Products STRICTLY CONFIDENTIAL Actemra has obtained regulatory approval in 116 countries and has been delivered to over 690,000 Japanese patients in total after its release in Japan. In 2025, Actemra celebrates its 2
Slide 55: Contacts
Contacts Corporate Communications Dept. For Media: Media Relations Group Tel： +81 (0)3-3273-0881 E-mail： pr@chugai-pharm.co.jp Person in Hideki Sato, Shumpei Yokoyama, Naoki Kouzai, charge： Ikue Miyazawa, Mari Otsuka For Investors: Investor Relations Group Tel： +81 (0)3-3273-0554 E-mail： ir@chugai-p
Slide 56: INNOVATION BEYOND IMAGINATION
INNOVATION BEYOND IMAGINATION [J CHUGAI PHARMACEUTICAL ‘A member of the Roche group